Abstract:Objective:To compare the prognosis of mildly or severely symptomatic patients with obstructive hypertrophic cardiomyopathy (OHCM) who underwent alcohol septal ablation (ASA).Methods:This retrospective study cohort consisted of patients with OHCM who received ASA treatment in Beijing Anzhen Hospital, Capital Medical University from March 2001 to August 2021. These patients were divided into mildly and severely symptomatic groups according to the severity of clinical symptoms. Long-term follow-up was conducted, and the following data were collected: duration of follow-up, postoperatire treatment, New York Heart Association (NYHA) classification, arrhythmia events and pacemaker implantation, echocardiographic parameters, and cause of death. Overall survival and survival free from OHCM-related death were observed, and the improvement of clinical symptoms and resting left ventricular outflow tract gradient (LVOTG) and the incidence of new-onset atrial fibrillation were evaluated. The Kaplan-Meier method and log-rank test were used to determine and compare the cumulative survival rates of the different groups. Cox regression analysis models were used to determine predictors of clinical events.Results:A total of 189 OHCM patients were included in this study, including 68 in the mildly symptomatic group and 121 in the severely symptomatic group. The median follow-up of the study was 6.0 (2.7, 10.6) years. There was no statistical difference in overall survival between the mildly symptomatic group (5-year and 10-year overall survival were 97.0% and 94.4%, respectively) and the severely symptomatic group (5-year and 10-year overall survival were 94.2% and 83.9%, respectively, P=0.405); there was also no statistical difference in survival free from OHCM-related death between the mildly symptomatic group (5-year and 10-year survival free from HCM-related death were 97.0% and 94.4%, respectively) and the severely symptomatic group (5-year and 10-year survival free from HCM-related death were 95.2% and 92.6%, respectively, P=0.846). In the mildly symptomatic group, NYHA classification was improved after ASA ( P<0.001), among which 37 patients (54.4%) were in NYHA class Ⅰ, and the resting left ventricular outflow tract gradient (LVOTG) decreased from 67.6 (42.7, 90.1) mmHg (1 mmHg=0.133 kPa) to 24.4 (11.7, 35.6) mmHg ( P<0.001). In severely symptomatic group, NYHA classification was also improved post ASA ( P<0.001), among which 96 patients (79.3%) improved by at least one NYHA classification, and the resting LVOTG decreased from 69.6 (38.4, 96.1) mmHg to 19.0 (10.6, 39.8) mmHg ( P<0.001). The incidence of new-onset atrial fibrillation was similar between the mildly and severely symptomatic groups (10.2% vs. 13.3%, P=0.565). Cox multivariate regression analysis showed that age was an independent predictor of all-cause mortality in OHCM patients post ASA ( HR=1.068, 95% CI 1.002-1.139, P=0.042). Conclusions:Among patients with OHCM treated with ASA, overall survival and survival free from HCM-related death were similar between mildly symptomatic group and severely symptomatic group. ASA therapy can effectively relieve resting LVOTG and improve clinical symptoms in mildly or severely symptomatic patients with OHCM. Age was an independent predictor of all-cause mortality in OHCM patients post ASA.

Progress in Comparison of Percutaneous Transluminal Septal Myocardial Ablation Versus Septal Myectomy for Treatment of Patients with Hypertrophic Obstructive Cardiomyopathy

Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy: Acute Results and Three-Year Noninvasive Follow-Up in 18 Patients.

The Effect on Electrocardiographic and Cardiac Autonomic Function after Percutaneous Transluminal Septal Myocardial Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy

A three-year follow-up comparative study for treating hypertrophic obstructive cardiomyopathy with percutaneous transluminal septal myocardial ablation or septal myectomy

Influence of percutaneous transluminal septal myocardial ablation of hypertrophic obstructive cardiomyopathy on mitral regurgitation

Selective Interventricular Septal Radiofrequency Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: Who Can Benefit?

A Modified Endocardial Radiofrequency Ablation Approach for Hypertrophic Obstructive Cardiomyopathy Guided by Transthoracic Echocardiography: a Case Series

Comparison of Clinical Outcomes and Postoperative Recovery Between Two Open Heart Surgeries:Minimally Invasive Right Subaxillary Vertical Thoracomy and Traditional Median Sternotomy

Therapeutic Effects of Alcohol Septal Ablation in Mildly Symptomatic Patients with Hypertrophic Obstructive Cardiomyopathy

Results after Percutaneous Transluminal Septal Myocardial Ablation of Hypertrophic Obstructive Cardiomyopathy

Efficacy of Alcohol Septal Ablation in Mildly Symptomatic or Severely Symptomatic Patients with Hypertrophic Obstructive Cardiomyopathy

Long-term Efficiency of Percutaneous Transluminal Septal Myocardial Ablation for Treating the Patients With Hypertrophic Obstructive Cardiomyopathy

Midterm Outcomes of Percutaneous Transluminal Septal Myocardial Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy Refractory to Medication.

Clinical Evaluation of Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy

In-hospital outcomes of septal myectomy vs. alcohol septal ablation for hypertrophic cardiomyopathy with outflow tract obstruction: An update and insights from the national inpatient sample from 2011 to 2019

Transcatheter Myotomy for Hypertrophic Obstructive Cardiomyopathy

Trans-femoral transcatheter intramyocardial septal radiofrequency ablation: a novel therapeutic approach for obstructive hypertrophic cardiomyopathy

Transapical intramyocardial septal microwave ablation in treatment of hypertrophic obstructive cardiomyopathy: 12-month outcomes of a swine model

Treatment Strategies for Hypertrophic Cardiomyopathy: Surgical

Evaluation of Left Ventricular Myocardial Perfusion and Function Using Gated Spect in Patients with Hypertrophic Obstruction Cardiomyopathy Following Percutaneous Transluminal Septal Myocardial Ablation

Non-pharmaceutical Interventions for Hypertrophic Cardiomyopathy: A Mini Review